SG/PUT/MODERNA/80/0.1/20.12.24 | Market Closed - Euronext Paris 10:00:01 20/06/2024 pm IST | ||
| 0.235 EUR | -4.08% |
|
| Current month | +9.30% | ||
| 1 month | +20.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 20/24/20 | 0.235 | -4.08% |
| 19/24/19 | 0.245 | +8.89% |
| 18/24/18 | 0.225 | +9.76% |
| 17/24/17 | 0.205 | 0.00% |
| 14/24/14 | 0.205 | +17.14% |
Real-time Euronext Paris
Last update June 20, 2024 at 10:00 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | 
Société Générale
|
| U614S | |
| ISIN | DE000SU671V9 |
| Date issued | 22/01/2024 |
| Strike | 80 $ |
| Maturity | 20/12/2024 (183 Days) |
| Parity | 10 : 1 |
| Emission price | 1.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.265 € |
|---|---|
| Lowest since issue | 0.12 € |
| Spread | 0.01 € |
| Spread % | 4.17% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
133.3
USD
Average target price
145.2
USD
Spread / Average Target
+8.97%
- Stock Market
- Warrants
- U614S Warrant
